Fmr LLC Madrigal Pharmaceuticals, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Fmr LLC holds 789,003 shares of MDGL stock, worth $184 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

789,003

Previous 713,914 10.52%

Holding current value

$184 Million

Previous $191 Million 15.95%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$193.33 - $291.99 $14.5 Million - $21.9 Million	75,089 Added 10.52%	789,003 $221 Million
Q1 2024 May 13, 2024	BUY	$171.37 - $283.23 $15.2 Million - $25.1 Million	88,749 Added 14.2%	713,914 $191 Million
Q4 2023 Feb 13, 2024	BUY	$120.4 - $237.13 $22.2 Million - $43.8 Million	184,785 Added 41.96%	625,165 $145 Million
Q3 2023 Nov 13, 2023	BUY	$146.04 - $225.78 $13.3 Million - $20.6 Million	91,337 Added 26.17%	440,380 $64.3 Million
Q2 2023 Aug 11, 2023	BUY	$203.88 - $312.0 $17.7 Million - $27 Million	86,600 Added 33.0%	349,043 $80.6 Million
Q1 2023 May 11, 2023	BUY	$231.06 - $307.08 $14.8 Million - $19.6 Million	63,953 Added 32.22%	262,443 $63.6 Million
Q4 2022 Feb 13, 2023	BUY	$58.39 - $296.54 $2.03 Million - $10.3 Million	34,716 Added 21.2%	198,490 $57.6 Million
Q3 2022 Nov 10, 2022	BUY	$60.57 - $79.51 $9,691 - $12,721	160 Added 0.1%	163,774 $10.6 Million
Q2 2022 Aug 12, 2022	SELL	$58.04 - $100.2 $29,310 - $50,601	-505 Reduced 0.31%	163,614 $11.7 Million
Q1 2022 May 13, 2022	SELL	$55.89 - $101.89 $135,309 - $246,675	-2,421 Reduced 1.45%	164,119 $16.1 Million
Q2 2021 Aug 13, 2021	BUY	$97.2 - $137.59 $16.2 Million - $22.9 Million	166,540 New	166,540 $16.2 Million

Others Institutions Holding MDGL

# of Institutions

297

Shares Held

22M

Call Options Held

757K

Put Options Held

370K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $3.99B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account